Autologous Transplantation Improves Survival Rates for Follicular Lymphoma Patients Who Relapse within 2-Years of Chemoimmunotherapy: A Multi-Centre Retrospective Analysis of Consecutively Treated Patients in the Real World

Introduction: Although rituximab-based chemoimmunotherapy (RChemo) significantly improves overall survival (OS) for follicular lymphoma (FL), approximately 20% of patients experience initial time to progression (TTP1) of ≤2 years (early relapse) and relatively poor OS. We conducted a retrospective study to evaluate OS rates for patients with early relapse who were treated with or without high dose therapy and autologous stem cell …